MedPage Today -- BRUSSELS -- Choosing the best breast cancer chemotherapy to accompany the novel class of drugs targeting PARP, an enzyme crucial to DNA repair in cancer cells, won’t be an easy battle, according to a panel of experts.
MedPage Today -- BRUSSELS -- Choosing the best breast cancer chemotherapy to accompany the novel class of drugs targeting PARP, an enzyme crucial to DNA repair in cancer cells, won’t be an easy battle, according to a panel of experts.
